HOME >> BIOLOGY >> NEWS
Einstein's Dr. Vern Schramm elected to the National Academy of Sciences

May 1, 2007 (BRONX, NY) -- Vern L. Schramm, Ph.D., Professor and Ruth Merns Chair of Biochemistry at the Albert Einstein College of Medicine of Yeshiva University, has been elected to the National Academy of Sciences, the nations most prestigious honorary society for scientists. His election was announced today at the Academys annual meeting in Washington, D.C.

Dr. Schramm has been a member of the Einstein faculty since 1987. Throughout his career, he has carried out groundbreaking research into the mechanisms involved in enzymatic reactions. This work has led to promising drugs now being tested in clinical trials for treating autoimmune diseases and several types of cancer.

Dr. Schramm studies the transition-state structure of enzyme-catalyzed reactions the shapes that reacting molecules assume when enzymes catalyze chemical reactions. As he describes it, Enzymes govern virtually all of the chemical transformations necessary for biological life but can also influence cells to become cancerous. By knowing the transition-state structure of enzyme-catalyzed reactions, we can design powerful inhibitors that can block those enzymes from acting and thereby treat or prevent cancer and other diseases.

One such inhibitor that Dr. Schramm has designed, known as Immucillin-H, is a promising anticancer agent for treating T-cell malignancies. It is currently in a pivotal phase IIb clinical trial (specifically targeted to study efficacy) at sites in the U.S., eastern and western Europe, and South America.

Another transition-state inhibitor developed by Dr. Schramm is now being studied as a possible treatment for autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disorders and for preventing the rejection of transplanted organs.

The election to the Academy is the latest among numerous honors recognizing Dr. Schramms many contributions in more than 35 years as a biochemistr
'"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
4-May-2007


Page: 1 2

Related biology news :

1. Einsteins Dr. E. Richard Stanley receives 2006 E. Donnall Thomas Prize
2. Einsteins Susan Band Horwitz, PhD wins Bristol-Myers Squibb Cancer Research Award
3. Candidate research sites selected for the National Ecological Observatory Network
4. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
5. CSHL selected for odENCODE Data Coordination Center
6. University of Arizona neurobiologist John Hildebrand elected to the National Academy of Sciences
7. 5 Stanford professors elected to National Academy of Sciences
8. Salk scientist Ursula Bellugi elected to National Academy of Sciences
9. Psychology professor elected to American Academy of Arts and Sciences
10. ORNLs Thundat elected fellow of AAAS
11. Leading scientists elected to EMBO ranks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
(Date:6/23/2020)... England (PRWEB) , ... June 23, 2020 , ... ... Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of ... project to support testing operations in the fight against the COVID-19 pandemic in ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... 29, 2020 , ... R3 Stem Cell International is now offering patients the ... stem cells total, patients may choose which extremities they would like treated. , Several ... Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab ...
(Date:7/31/2020)... ... , ... eSource has long been touted as the solution to high data ... the reasons it did not take off as quickly as people initially expected, and ... moving towards capturing data electronically for clinical trials and then repurposing it for downstream ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... ... July 09, 2020 , ... In most research ... to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic ... MA has been using the zebrafish model to investigate the causes of leukaemia ...
Breaking Biology Technology:
Cached News: